Price (delayed)
$83.11
Market cap
$103.47B
P/E Ratio
97.78
Dividend/share
$3.06
EPS
$0.85
Enterprise value
$124.05B
Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the
Highlights
Gilead Sciences's debt has decreased by 8% YoY and by 7% QoQ
The company's net income has surged by 118% QoQ but it has shrunk by 81% YoY
GILD's EPS has surged by 113% since the previous quarter but it has dropped by 81% year-on-year
GILD's P/E is 31% above its last 4 quarters average of 74.4 and 30% above its 5-year quarterly average of 75.2
The quick ratio has contracted by 12% YoY and by 4.2% from the previous quarter
Key stats
What are the main financial stats of GILD
Market
Valuations
Earnings
Shares outstanding
1.24B
Market cap
$103.47B
Enterprise value
$124.05B
Price to earnings (P/E)
97.78
Price to book (P/B)
5.66
Price to sales (P/S)
3.74
EV/EBIT
48.95
EV/EBITDA
23.45
EV/Sales
4.46
Revenue
$27.81B
EBIT
$2.53B
EBITDA
$5.29B
Free cash flow
$6.9B
Per share
Balance sheet
Liquidity
EPS
$0.85
Free cash flow per share
$5.51
Book value per share
$14.67
Revenue per share
$22.23
TBVPS
$17.93
Total assets
$53.58B
Total liabilities
$35.38B
Debt
$23.35B
Equity
$18.28B
Working capital
$1.54B
Debt to equity
1.28
Current ratio
1.14
Quick ratio
0.69
Net debt/EBITDA
3.89
Margins
Efficiency
Dividend
EBITDA margin
19%
Gross margin
75.7%
Net margin
3.8%
Operating margin
9.2%
Return on assets
1.8%
Return on equity
5.2%
Return on invested capital
7.6%
Return on capital employed
5.9%
Return on sales
9.1%
Dividend yield
3.68%
DPS
$3.06
Payout ratio
360%
GILD stock price
How has the Gilead Sciences stock price performed over time
Intraday
0.07%
1 week
2.68%
1 month
12.65%
1 year
9.9%
YTD
2.59%
QTD
21.13%
Financial performance
How have Gilead Sciences's revenue and profit performed over time
Revenue
$27.81B
Gross profit
$21.05B
Operating income
$2.56B
Net income
$1.05B
Gross margin
75.7%
Net margin
3.8%
The company's net income has surged by 118% QoQ but it has shrunk by 81% YoY
Gilead Sciences's net margin has surged by 111% QoQ but it has shrunk by 81% YoY
The operating margin has plunged by 70% YoY but it has soared by 61% from the previous quarter
The operating income has dropped by 70% year-on-year but it has surged by 62% since the previous quarter
Growth
What is Gilead Sciences's growth rate over time
Valuation
What is Gilead Sciences stock price valuation
P/E
97.78
P/B
5.66
P/S
3.74
EV/EBIT
48.95
EV/EBITDA
23.45
EV/Sales
4.46
GILD's EPS has surged by 113% since the previous quarter but it has dropped by 81% year-on-year
GILD's P/E is 31% above its last 4 quarters average of 74.4 and 30% above its 5-year quarterly average of 75.2
The stock's price to book (P/B) is 29% more than its 5-year quarterly average of 4.4 and 23% more than its last 4 quarters average of 4.6
Gilead Sciences's equity has decreased by 14% YoY but it has increased by 4.2% from the previous quarter
GILD's price to sales (P/S) is 10% more than its 5-year quarterly average of 3.4 and 10% more than its last 4 quarters average of 3.4
Efficiency
How efficient is Gilead Sciences business performance
The company's return on equity has surged by 126% QoQ but it has shrunk by 80% YoY
GILD's return on assets has surged by 125% since the previous quarter but it has dropped by 80% year-on-year
GILD's return on sales has dropped by 70% year-on-year but it is up by 21% since the previous quarter
Gilead Sciences's ROIC has plunged by 69% YoY but it has increased by 23% from the previous quarter
Dividends
What is GILD's dividend history
DPS
$3.06
Dividend yield
3.68%
Payout ratio
360%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The total liabilities has contracted by 14% YoY and by 9% from the previous quarter
GILD's total assets is down by 14% YoY and by 4.8% QoQ
Gilead Sciences's debt is 28% higher than its equity
Gilead Sciences's equity has decreased by 14% YoY but it has increased by 4.2% from the previous quarter
The company's debt to equity fell by 11% QoQ but it rose by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.